ORIEN Cancer Data Network Adds Collaborators
News Jul 13, 2015
"Becoming part of ORIEN adds great opportunities for Rutgers Cancer Institute of New Jersey, enabling discovery based on large-scale, diverse population data as well as patient-specific clinical decision support across a broad, national clinical trial portfolio," Robert DiPaola, director of the Rutgers Cancer Institute of New Jersey, said in a statement.
ORIEN was launched in May 2014 by the Moffitt Cancer Center and Ohio State University Comprehensive Cancer Center to bring together data to drive research collaborations in oncology and personalized medicine. With the new additions, the network now has nine members.
In February, City of Hope, University of Virginia Cancer Center, University of Colorado Cancer Center, and University of New Mexico Cancer Center joined ORIEN.
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.READ MORE
18th International Conference on Pharmaceutics & Novel Drug Delivery Systems
May 27 - May 28, 2019